AstraZeneca said Monday that late-stage trials showed that its COVID-19 vaccine with Oxford University was up to 90% effective in preventing disease. The results are based on interim analysis of trials in the U.K. and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of COVID-19 were reported in those receiving the vaccine, AstraZeneca said. The trial looked at two different dosing regimens. A half dose of the vaccine followed by a full dose at least one month apart was 90% effective. A second regimen using two full doses one month apart was 62% effective. The combined results showed an average efficacy rate of 70%. “These findings show that we have an effective vaccine that will save many lives,” Professor Andrew Pollard, chief investigator for the trial, said in a statement. “Excitingly, we’ve found that one of our […]